Obermeyer Wealth Partners’s AbbVie ABBV Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$2.73M Sell
10,832
-19
-0.2% -$4.09K 0.11% 71
2026
Q1
$2.36M Buy
10,851
+245
+2% +$54.3K 0.11% 69
2025
Q4
$2.42M Buy
10,606
+104
+1% +$23.7K 0.11% 71
2025
Q3
$2.43M Sell
10,502
-1,301
-11% -$265K 0.11% 65
2025
Q2
$2.19M Sell
11,803
-12,006
-50% -$2.23M 0.11% 73
2025
Q1
$4.99M Buy
23,809
+617
+3% +$120K 0.27% 49
2024
Q4
$4.12M Buy
23,192
+4,491
+24% +$826K 0.21% 51
2024
Q3
$3.69M Buy
18,701
+265
+1% +$49.5K 0.2% 52
2024
Q2
$3.16M Buy
18,436
+363
+2% +$60.1K 0.18% 53
2024
Q1
$3.29M Buy
18,073
+7,613
+73% +$1.31M 0.19% 49
2023
Q4
$1.62M Buy
10,460
+120
+1% +$17.5K 0.11% 57
2023
Q3
$1.54M Buy
10,340
+419
+4% +$61.5K 0.11% 53
2023
Q2
$1.34M Sell
9,921
-316
-3% -$46.3K 0.1% 60
2023
Q1
$1.63M Sell
10,237
-1,027
-9% -$157K 0.12% 57
2022
Q4
$1.82M Sell
11,264
-270
-2% -$41.4K 0.14% 56
2022
Q3
$1.55M Sell
11,534
-385
-3% -$55.2K 0.13% 56
2022
Q2
$1.83M Buy
11,919
+677
+6% +$103K 0.13% 50
2022
Q1
$1.82M Sell
11,242
-9
-0.1% -$1.31K 0.11% 53
2021
Q4
$1.52M Sell
11,251
-16
-0.1% -$1.89K 0.08% 59
2021
Q3
$1.22M Sell
11,267
-222
-2% -$25.4K 0.07% 64
2021
Q2
$1.29M Buy
11,489
+684
+6% +$77K 0.07% 67
2021
Q1
$1.17M Buy
10,805
+4,094
+61% +$438K 0.07% 67
2020
Q4
$719K Buy
6,711
+165
+3% +$15.9K 0.05% 70
2020
Q3
$573K Sell
6,546
-239
-4% -$22.5K 0.04% 77
2020
Q2
$666K Buy
6,785
+127
+2% +$11.2K 0.06% 60
2020
Q1
$507K Sell
6,658
-373
-5% -$31.8K 0.05% 66
2019
Q4
$623K Sell
7,031
-283
-4% -$23.5K 0.06% 72
2019
Q3
$554K Sell
7,314
-800
-10% -$54.8K 0.05% 72
2019
Q2
$590K Buy
8,114
+503
+7% +$39.5K 0.05% 73
2019
Q1
$613K Sell
7,611
-350
-4% -$28.6K 0.06% 66
2018
Q4
$734K Hold
7,961
0.07% 61
2018
Q3
$753K Buy
7,961
+631
+9% +$59.8K 0.06% 62
2018
Q2
$679K Sell
7,330
-344
-4% -$33.6K 0.06% 62
2018
Q1
$726K Sell
7,674
-875
-10% -$96.1K 0.07% 60
2017
Q4
$827K Buy
8,549
+1,564
+22% +$147K 0.07% 64
2017
Q3
$621K Sell
6,985
-108
-2% -$8.22K 0.05% 72
2017
Q2
$514K Buy
7,093
+234
+3% +$15.7K 0.05% 77
2017
Q1
$447K Sell
6,859
-3,770
-35% -$237K 0.04% 87
2016
Q4
$666K Sell
10,629
-700
-6% -$42.7K 0.06% 67
2016
Q3
$715K Hold
11,329
0.07% 63
2016
Q2
$701K Buy
11,329
+2,208
+24% +$135K 0.07% 61
2016
Q1
$521K Sell
9,121
-759
-8% -$42.3K 0.05% 72
2015
Q4
$585K Sell
9,880
-602
-6% -$34.7K 0.05% 63
2015
Q3
$570K Buy
10,482
+58
+0.6% +$3.77K 0.06% 63
2015
Q2
$700K Buy
10,424
+255
+3% +$16.6K 0.06% 69
2015
Q1
$595K Hold
10,169
0.05% 84
2014
Q4
$665K Buy
+10,169
New +$641K 0.06% 84
2013
Q3
Sell
-2,861
Closed -$118K 61
2013
Q2
$118K Buy
+2,861
New +$125K 0.03% 73

Other funds holding ABBV

Obermeyer Wealth Partners's ABBV Position: Q2 2026 in Review

Obermeyer Wealth Partners reduced its AbbVie (ABBV) stake by 0.18% in Q2 2026, selling an estimated $4.09K and leaving 10,832 shares worth $2.73M. The position accounts for 0.11% of the portfolio, ranked #71.

Obermeyer Wealth Partners first reported a position in ABBV in Q2 2013 and has held it in 48 quarters since. The position peaked at $4.99M in Q1 2025. 4,201 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.

  • Obermeyer Wealth Partners held 10,832 shares of AbbVie worth $2.73M as of Q2 2026.
  • Obermeyer Wealth Partners sold 19 AbbVie shares in Q2 2026, an estimated $4.09K.
  • AbbVie made up 0.11% of Obermeyer Wealth Partners's portfolio in Q2 2026, its #71 holding.
  • Obermeyer Wealth Partners first reported a position in AbbVie in Q2 2013 and has held it in 48 quarters since.
  • Obermeyer Wealth Partners's AbbVie position peaked at $4.99M in Q1 2025.
  • 4,201 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.

Based on Obermeyer Wealth Partners's 13F filing for Q2 2026, filed 29 Jul 2026.